JAMA Neurology publishes vamorolone data in DMD

US journal JAMA Neurology has published positive results of the 24-week primary efficacy and safety analysis from the VISION-DMD study evaluating vamorolone, an investigational drug for the treatment Duchenne muscular dystrophy (DMD).

Switzerland’s Santhera Pharmaceuticals (SIX: SANN) acquired global rights to vamorolone from privately-held US firm ReveraGen in September 2020, having taken an option on the drug two years earlier.

The companies are set to submit filings for the drug in Europe and the USA later this year, and will see the JAMA Neurology publication as a helpful reminder for regulators and physicians of the supporting data.